The litigation alleges that Embecta violated the Securities Exchange Act of 1934 by providing false and misleading fiscal guidance to the market. According to the complaint, company leadership maintained an optimistic outlook for the second quarter and full-year 2026 despite being aware of significant headwinds in the pen needle market. These undisclosed pressures eventually eroded the company’s performance, leading to financial losses for shareholders once the true state of the business became public.

Attorneys Brian Schall and David Schwartz are inviting affected investors to discuss potential recovery options. While the court has not yet certified the class, eligible participants must act by August 17, 2026, to pursue lead plaintiff status. Representation is not automatic for those who hold shares; absent members who choose not to join the litigation will remain unrepresented in the proceedings.